Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,580.06
(
0.22%
)
US TECH 100
29,506.00
(
0.28%
)
Dow Jones
51,032.46
(
0.72%
)
Brent Oil
92.52
(
1.26%
)
Bitcoin
73,740.49
(
0.25%
)
News Focus
News Focus
Post# of 257662
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 123040
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: acgood post# 86100

Tuesday, 11/10/2009 7:24:49 PM

Tuesday, November 10, 2009 7:24:49 PM

Post# of 257662

When Teva wants to offer a new delivery option for Copaxone (ie, the autoject2 is now available to use with the prefilled syringes), what sort of regulatory filing process is required? I.e., if Copaxone was another Teva-Antares partner product, what regulatory path would it take?

The answer to both questions is a supplemental NDA.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today